Early Alert: Diagnostic Ultrasound System Issue From Philips Ultrasound

TL;DR

For listenersOffer from Amazon

Turn quiet afternoons into listening time

• Thousands of audiobooks, podcasts and originals
• Listen on your phone, tablet or Echo — also offline
• Cancel anytime

Try Audible free →Free trial for new members

As an affiliate, we earn on qualifying purchases.Hide

The FDA issued an Early Alert about Philips Lumify diagnostic ultrasound systems after reports of unexpected transducer re-registration and unstable cable connections. Philips reported eight serious injuries and four deaths associated with the issue as of September 29, 2026; the FDA says it is reviewing information, and Philips is working on software and connection-related solutions.

The U.S. Food and Drug Administration has issued an Early Alert about Philips Lumify diagnostic ultrasound systems after reports that software may unexpectedly require users to re-register a transducer, preventing scans until registration is complete. Philips reported eight serious injuries and four deaths associated with the issue as of September 29, 2026; the FDA says it is reviewing the information and will update its notice as significant new details become available.

According to the FDA, Philips told affected customers that a software issue in the Lumify Android or iOS application may cause it not to recognize a previously registered transducer. The app can prompt for re-registration without warning before point-of-care use. Because registration requires Wi-Fi or cellular access, users may be unable to scan if the prompt appears where those signals are unavailable.

Philips has received reports of unexpected re-registration events preventing scans in pre-hospital settings and delaying care. The reports described by the company involved circumstances outside Wi-Fi or cellular coverage. The FDA also relayed a separate concern from Philips: the transducer’s USB cable connection to a phone or tablet may disconnect or become unstable during use, interrupting continuous operation and potentially delaying care.

Philips sent a letter to affected customers on September 24, 2026, recommending that users operate Lumify only where Wi-Fi or cellular signals are readily accessible, unless a backup ultrasound device is immediately available. It also advised facilities to keep backup ultrasound devices or modalities available, share the notice with users, and post it near affected units. The FDA alert lists affected Lumify software versions for both iOS and Android.

Why Scan Interruptions Matter in the Field

Lumify is designed for point-of-care imaging and can be used in ambulances and other settings outside hospitals. In these environments, clinicians may use ultrasound to support rapid diagnosis, triage, and treatment decisions. A system that cannot scan when needed may remove an imaging option at a time when staff have limited equipment or limited access to technical support.

The FDA warns that loss of function or system failure during a procedure may delay diagnosis or treatment. The potential consequences depend on the patient’s condition and clinical circumstances; the agency says such delays could lead to serious injury or death. The reported totals are Philips’ figures conveyed in the FDA notice, not a determination in the alert that the device issue caused each outcome.

The recommendations address the immediate operational risk: maintain a usable connection for registration and have another ultrasound device or modality ready. These steps are especially relevant for teams working in mobile, remote, or underserved locations where connectivity and replacement equipment may not be readily available.

How the Lumify System Works

The Lumify system combines a Philips transducer, the Philips Lumify application, and a compatible Android or iOS phone or tablet. It is indicated for diagnostic ultrasound imaging and fluid-flow analysis and is intended for healthcare settings. Its transportable design allows use outside hospitals, including in ambulances.

The FDA alert identifies affected versions of the application across both operating systems. The listed iOS versions are 2.X, 5.0, 5.1.2 and 5.1.3; listed Android versions are 1.X, 3.X, 4.X, 5.1 and 5.1.1. The notice also provides corresponding Unique Device Identifier (UDI) codes to help identify devices. Users should refer to Philips’ customer communication and the FDA notice to determine whether their equipment is included.

The alert describes two separate functional concerns: unexpected re-registration, for which Philips is developing a software update, and possible USB cable disconnection or instability, for which Philips is still assessing the cause and a suitable solution. The FDA characterizes the issue as potentially high-risk and says its review is ongoing.

“Philips stated it is developing a software update to address the registration issue.”

— Philips Ultrasound, as summarized by the FDA

Remaining Questions on Scope and Fixes

The FDA notice does not specify how many Lumify systems or customers have experienced either functional problem, how often the events occur, or how the reported injuries and deaths relate individually to the registration and cable issues. Philips reported eight serious injuries and four deaths associated with the issue as of September 29, but the alert does not provide case details or say that each outcome has been independently confirmed as caused by a device failure.

The timing of the software update is also not stated. Philips is assessing the cable-connection problem, and the notice gives no confirmed cause, final corrective action, or expected release date for a solution. The FDA says it will post updates as significant new information becomes available.

Customer Notices and FDA Updates

Philips said it will send customers a follow-up communication when the software update is available and will provide instructions on any action required. It also said it will share further information about the cable issue as it becomes available. Until then, the company’s stated precautions are to use Lumify only where Wi-Fi or cellular service is readily accessible unless a backup ultrasound device is immediately available, and to keep backup devices or modalities available for care.

Healthcare organizations should circulate Philips’ letter to device users and post the notice near affected units, as the company recommended. The FDA advises users to check its alert page for updates. U.S. customers with questions or reports of a quality problem or adverse reaction can contact the Philips Ultrasound Customer Care Solutions Center at (800) 722-9377. Healthcare professionals and consumers may also report problems through the FDA’s MedWatch program.

Key Questions

What problem did the FDA alert identify?

The FDA says Philips reported that Lumify software may fail to recognize a previously registered transducer and request re-registration without warning. Scanning cannot resume until registration is completed, which requires Wi-Fi or cellular service. Philips also reported possible USB cable disconnections or unstable connections during use.

Which Philips Lumify systems are listed?

The alert lists Lumify app versions 2.X, 5.0, 5.1.2 and 5.1.3 for iOS, and 1.X, 3.X, 4.X, 5.1 and 5.1.1 for Android. Users should check the FDA notice and Philips’ customer letter for the applicable device identifiers and instructions.

What should users do while a fix is pending?

Philips recommends using Lumify where Wi-Fi or cellular signals are readily accessible unless a backup ultrasound device is immediately available. It also recommends keeping backup ultrasound devices or modalities available for care and sharing and posting the customer notice.

Has Philips released a software update?

Not according to the FDA notice. Philips said it was developing an update for the registration problem and would send a follow-up communication when it became available. The timing and required actions have not been provided.

How can users report a problem?

U.S. customers can contact the Philips Ultrasound Customer Care Solutions Center at (800) 722-9377. Healthcare professionals and consumers can also report adverse reactions or quality problems through the FDA’s MedWatch program.

Source: primary